# IMM Investment

> IMM Investment is a VC fund in Kangnam backing Biotechnology and Health Care. See 269 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Kangnam, South Korea
- Total investments: 269
- Last investment: Aug 2026
- Lead investor: 15%
- Fund size: $25M
- Last fund: Jul 2016
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/imm-investment/about/
- Website: http://imm.co.kr/

IMM Investment is an independent venture capital firm focused on investments in venture capital, mezzanine, and infrastructure.With the longstanding trust of institutional investors, partners and investment professionals continue to create significant values for Portfolio companies, which consist of information technology,healthcare/biotech, and manufacturing.

## Contacts

5 contacts available for IMM Investment. Shizune tracks 6 team members at IMM Investment. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/imm-investment?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $3M–$55M |
| Series B | $5.9M–$72M |
| Series C | $7.7M–$46M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 34 | 13% |
| Health Care | 33 | 12% |
| Artificial Intelligence | 33 | 12% |
| Software | 31 | 12% |
| Medical | 23 | 9% |

217 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 57 | 21% |
| Series B | 55 | 20% |
| Series C | 38 | 14% |
| Funding Round | 27 | 10% |
| Venture - Series Unknown | 27 | 10% |

16 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| South Korea | 154 | 57% |
| United States | 19 | 7% |
| Japan | 6 | 2% |
| India | 3 | 1% |
| Singapore | 2 | 1% |

13 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Hyun-Chan Cho | Managing Partner | 4 | https://shizune.co/investors/profile/hyun-chan-cho |
| Kustin Lee | CIO | 1 | https://shizune.co/investors/profile/kustin-lee |
| Sukyoung Cho | Manager | 2 | https://shizune.co/investors/profile/sukyoung-cho |
| Sung- Bae Ji | CEO, President & Partner | 0 | https://shizune.co/investors/profile/sung-bae-ji-90d8 |
| Timothy Chang | Co-Founder, Chief Executive Officer, Partner & President | 0 | https://shizune.co/investors/profile/timothy-chang-7419 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| N.Light | N.Light is a Metaverse 3D design software that allows individuals to effortlessly turn their ideas into reality. | $10.6M | Venture - Series Unknown | Aug 10, 2026 |  |
| ArcGen Bioscience | ArcGen Bioscience is a biopharmaceutical development company focused on researching, developing, and advancing innovative therapeutic solutions to address unmet medical needs through cutting-edge biotechnology and drug development. | $6.7M | Series A | Jul 13, 2026 |  |
| CarbonSix | CarbonSix develops AI-powered robotics technologies for manufacturing automation, with a focus on tasks that involve high product variation and changing production conditions. Its platform uses imitation learning to enable industrial robots to learn from human demonstrations and perform complex manipulation tasks that are difficult to automateusing conventional programming methods. The company combines robotics hardware and AI software to improve robot adaptability while meeting industrial quality and reliability requirements. Its solutions are designed for manufacturing environments where flexible automation is needed for assembly and other variable production processes. | $40M | Series A | Jul 01, 2026 |  |
| Inocras | Inocras Inc. specializes in whole genome sequencing and analytics, focusing on providing insights for personalized care in cancer and rare diseases. Utilizing artificial intelligence, Inocras aims to revolutionize healthcare by enabling precision medicine. The company offers services to patients, healthcare providers, researchers, and partners,seeking to unlock new possibilities in precision health. With a commitment to innovation, Inocras has introduced products like CancerVision and RareVision, designed to enhance diagnosis and treatment strategies through comprehensive genomic analysis. | $20K | Series B | Jul 01, 2026 |  |
| Asteromorph | Asteromorph is an artificial intelligence (AI) research startup for the development of scientific superintelligence | $31.3M | Seed | May 29, 2026 |  |
| Caring | Caring is a visiting medical treatment facility that offers medical consultation. | $27.3M | Series C | May 08, 2026 |  |
| Mediwhale | Medi Whale seeks to achieve sustainable healthcare where every eye can truly be the window to one’s health with our world's first-of-its-kind 1-stop AI screening platform solution for cardiovascular, renal, metabolic risk assessment, and eye disease diagnosis. Our AI Platform was developed through several clinical collaborations (Korea,Singapore, India, UK, and other European datasets) using structured longitudinal event-based datasets for the development of our retinal biomarker engines. RetiCVD® (cardiovascular disease risk assessment): Developed using coronary artery calcium (CAC) score, CAC is recognized as the gold standard for precise CVD risk calculation. Our CVD engine predicts the presence of CAC and provides a stratified probabilistic risk based on US ASCVD and EU SCORE guidelines.RetiCKD® (chronic kidney disease risk assessment): Developed using eGFR and full lab panel, our CKD engine has been demonstrated to achieve better predictive capability as compared to eGFR or full panel analysis.RetiEYE®: Referable Eye Disease engine detects and flags common aging-related eye modalities such as diabetic retinopathy, age-related macular degeneration, glaucoma, and cataract at its referable disease state.Medi Whale retinal-based systemic biomarkers have been clinically demonstrated to be non-inferior to current gold standards and are recognized by clinical and scientific communities with two Lancet Digital Health publications. | $13.3M | Series C | Mar 27, 2026 |  |
| CLUSH | Clush is an AI and cloud infrastructure company that builds enterprise software to help organizations develop, deploy, and manage AI systems. The company offers cloud-native services and products, enabling customers to build, manage, and collaborate on cloud-based applications and data. Clush provides products such as Clush Kube MLOps, AIgovernance platforms, AI agents, hybrid cloud infrastructure, and enterprise collaboration tools for industries including finance, manufacturing, and public sector organizations | $26.3M | Venture - Series Unknown | Jan 27, 2026 |  |
| Roboe Technologies | Roboe Technologies is a South Korea–based AI robotics company focused on developing MOROW autonomous mobile robots and intelligent automation solutions. The company builds robotics systems for industrial environments, logistics, and service applications, aiming to improve efficiency, autonomy, and smart factory operations through AI-drivennavigation and control technologies. | $6.9M | Series A | Dec 30, 2025 |  |
| Orum Therapeutics | Orum Therapeutics is a private biotech company developing a new class of therapeutic antibodies targeting cytosolic proteins for unmet medical needs in cancer and rare diseases. Orum leverages its unique cell-penetrating antibody platform, called Oromab™ to inhibit drug targets, previously undruggable by small molecules or current antibodytherapeutics. In contrast to other approaches, Orum’s antibody platform can intracellularly deliver an active antibody therapeutic or payload, is easily adaptable to target different cell types and intracellular proteins, and does not require chemical modification. | $98.3M | Post-IPO Equity | Dec 18, 2025 |  |

10 of 269 investments shown.

## Co-investors
- [KB Investment](https://shizune.co/investors/profile/kbinvest) — VC Fund, 40 deals together
- [Korea Development Bank](https://shizune.co/investors/profile/korean-development-bank) — VC Fund, 28 deals together
- [Mirae Asset Venture Investment](https://shizune.co/investors/profile/mirae-asset-venture-investment) — VC Fund, 26 deals together
- [Korea Investment Partners](https://shizune.co/investors/profile/korea-investment-partners) — VC Fund, 23 deals together
- [Company K Partners](https://shizune.co/investors/profile/company-k) — VC Fund, 22 deals together
- [Smilegate Investment](https://shizune.co/investors/profile/smilegate-investment) — VC Fund, 22 deals together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Strong Ventures](https://shizune.co/investors/profile/strong-ventures) — VC Fund
- [Korea Credit Guarantee Fund](https://shizune.co/investors/profile/korea-credit-guarantee-fund) — VC Fund
- [Kakao Ventures](https://shizune.co/investors/profile/kakao-ventures) — VC Fund

## Featured in investor lists
- [All Investors in South Korea](https://shizune.co/investors/investors-south-korea)
- [All VC Funds in South Korea](https://shizune.co/investors/vc-funds-south-korea)
- [SaaS Investors in South Korea](https://shizune.co/investors/saas-investors-south-korea)
- [SaaS VC Funds in South Korea](https://shizune.co/investors/saas-vc-funds-south-korea)
- [Software VC Funds in South Korea](https://shizune.co/investors/software-vc-funds-south-korea)
- [Enterprise Investors in South Korea](https://shizune.co/investors/enterprise-investors-south-korea)

## FAQ

### What does IMM Investment invest in?

IMM Investment invests primarily in Biotechnology, Health Care and Artificial Intelligence startups, most often at Series A and Series B stage. Most of the 269 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is IMM Investment's check size?

IMM Investment typically joins rounds of $3M–$55M at Series A, $5.9M–$72M at Series B and $7.7M–$46M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds IMM Investment participates in.

### How do I contact IMM Investment?

Public channels for IMM Investment include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at IMM Investment?

The team at IMM Investment includes Hyun-Chan Cho (Managing Partner), Kustin Lee (CIO) and Sukyoung Cho (Manager), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co